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Abstract: Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease caused by the death of
motor neurons in the spinal cord and brainstem. ALS has a diverse genetic origin; at least 20 genes
have been shown to be related to ALS. Most familial and sporadic cases of ALS are caused by variants
of the SOD1, C9orf72, FUS, and TARDBP genes. Genome editing using clustered regularly interspaced
short palindromic repeats/CRISPR-associated system 9 (CRISPR/Cas9) can provide insights into the
underlying genetics and pathophysiology of ALS. By correcting common mutations associated with
ALS in animal models and patient-derived induced pluripotent stem cells (iPSCs), CRISPR/Cas9
has been used to verify the effects of ALS-associated mutations and observe phenotype differences
between patient-derived and gene-corrected iPSCs. This technology has also been used to create
mutations to investigate the pathophysiology of ALS. Here, we review recent studies that have used
CRISPR/Cas9 to understand the genetic underpinnings of ALS.
Keywords: amyotrophic lateral sclerosis (ALS); CRISPR/Cas9; induced pluripotent stem cells (iPSCs);
gene correction
1. Introduction
Amyotrophic lateral sclerosis (ALS) is the most common form of motor neuron disease (MND).
The term “amyotrophic” derives from “a”, which means no; “myo”, which means muscle; and
“trophic”, which refers to nourishment. Furthermore, “lateral” refers to the lateral corticospinal tracts
and “sclerosis” refers to scarring of lateral region [1]. Taken together, “amyotrophic lateral sclerosis”
denotes a lack of nourishment that leads to muscle wasting in the spinal cord, where descending
motor pathways carry motor signals from the brain down to the target muscle or organ. ALS, which is
diagnosed using an electromyography (EMG) test, is characterized by the loss of motor neurons and
muscle weakness, which results in respiratory failure and death within 3–5 years of onset [2].
A study in 1993 showed that the SOD1 gene was associated with some cases of ALS [3]. Since this
seminal study, the genetic etiology of ALS has expanded dramatically to include more than 20 different
genes (ALSoDs) [4]. The onset of ALS usually occurs in adulthood, but juvenile-onset ALS has been
observed in patients with mutations in the FUS gene [5]. There is no definitive cure for ALS, although
Riluzole increases patient survival by three months; the United States Food and Drug Administration
(FDA) has also recently approved a new treatment, Radicut [6–9].
Clustered regularly interspaced short palindromic repeats/CRISPR-associated system 9
(CRISPR/Cas9) genome-editing technology has advanced the field of genome engineering [10].
CRISPR/Cas9 has been adapted from a natural genome-editing system of bacteria. In the bacterial
immune system, bacteriophages recognize foreign genetic elements that occur as a result of infection
and destroy these foreign DNA fragments. The CRISPR/Cas9 system works similar to cut and replace
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DNA fragments. Although other genome editing tools exist, such as zinc finger nucleases (ZFNs)
and transcription activator-like effector nucleases (TALENs), CRISPR/Cas9 is simple and inexpensive
to use compared with prior tools [11,12]. In this review, we focus on recent studies that have used
CRISPR/Cas9-mediated gene correction and disease modeling to study ALS. In particular, we briefly
summarize and discuss prominent mutations in the SOD1, C9orf72, FUS, and TARDBP genes and their
roles in ALS, as revealed by CRISPR/Cas9 technology.
2. Amyotrophic Lateral Sclerosis (ALS)
ALS, also known as Lou Gehrig’s disease, is the most common MND. ALS is characterized by
muscle weakness and the loss of motor neurons in the spinal cord and brainstem. Clinical symptoms are
anatomically divided into two categories based on whether symptoms start in the limbs or bulbar region.
Limb onset displays symptoms in the upper (arm or hand) or lower limbs (leg or foot), and bulbar onset
patients have symptoms including weakness of muscle controls in speech and swallowing [13–15].
The age of onset is typically 55–60 years old, and the worldwide prevalence is approximately 1.68 per
100,000 individuals [16,17]. One study estimates that the proportion of individuals affected by ALS
will increase by 69% by 2040, primarily owing to a rapidly aging population [18]. The average survival
of patients with ALS is 2–5 years. Approximately 20% of patients survive for five years, eventually
succumbing to respiratory failure, whereas 5% of patients may live for 20 years [19,20].
There are two types of ALS, familial (fALS, 10% of cases) and sporadic (sALS, 90% of cases)
(Figure 1a). Since the discovery of superoxide dismutase 1 (SOD1) in 1993, over 20 genes have
been linked to ALS. According to the Amyotrophic Lateral Sclerosis online Database (ALSoD), over
100 genes may be linked to ALS [3,21,22]. Of these, the most common genetic causes of ALS involve
mutations in the SOD1, C9orf72, FUS, and TARDBP genes (Figure 1b). The Genome Aggregation
Database (gnomAD) provides whole-genome or exome sequences of various diseases. We explored
variants in SOD1, C9orf72, FUS, and TARDBP in the gnomAD v2.1.1 database as well as the Human
Genome Variation Society (HGVS) database from the National Institutes of Health (NIH) to gather
more information about each variant, including protein changes and dbSNPs (Table 1). Gene variants
are classified into five categories according to their clinical significance: pathogenic, likely pathogenic,
uncertain significance, likely benign, and benign [23]. There are 36 ALS-related variants in SOD1,
11 variants in FUS, and 14 variants in TARDBP with a pathogenic clinical significance. Variants in SOD1,
C9orf72, FUS, and TARDBP account for up to 60% of familial ALS and 10% of sporadic ALS; the cause
of the remaining cases remains unclear. The most common genetic cause of ALS is the (G4C2)n repeat
expansion in C9orf72 [2,24].
Figure 1. Genetic causes of amyotrophic lateral sclerosis (ALS). (a) Prevalence of familial and sporadic
ALS cases. (b) Proportion of causative genes in familial and sporadic ALS [25].
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Table 1. Amyotrophic lateral sclerosis (ALS)-associated pathogenic variants in SOD1, C9orf72, FUS,
and TARDBP (Genome Aggregation Database (gnomAD) v2.1.1).
Nucleotide Protein dbSNP Mutation Type
SOD1
NM_000454.4:c.14C >T NP_000445.1:p.Ala5Val rs121912442 Missense
NM_000454.4:c.20G >T NP_000445.1:p.Cys7Phe rs121912448 Missense
NM_000454.4:c.13G >A NP_000445.1:p.Ala5Thr rs121912444 Missense
NM_000454.4:c.37G >C NP_000445.1:p.Gly13Arg rs121912456 Missense
NM_000454.4:c.49G >A NP_000445.1:p.Gly17Ser rs121912453 Missense
NM_000454.4:c.64G >A NP_000445.1:p.Glu22Lys rs121912450 Missense
NM_000454.4:c.115C >G NP_000445.1:p.Leu39Val rs121912432 Missense
NM_000454.4:c.112G >C NP_000445.1:p.Gly38Arg rs121912431 Missense
NM_000454.4:c.112G >A NP_000445.1:p.Gly38Arg rs121912431 Missense
NM_000454.4:c.131A >G NP_000445.1:p.His44Arg rs121912435 Missense
NM_000454.4:c.125G >A NP_000445.1:p.Gly42Asp rs121912434 Missense
NM_000454.4:c.140A >G NP_000445.1:p.His47Arg rs121912443 Missense
NM_000454.4:c.124G >A NP_000445.1:p.Gly42Ser rs121912433 Missense
NM_000454.4:c.137T >G NP_000445.1:p.Phe46Cys rs121912457 Missense
NM_000454.4:c.217G >A NP_000445.1:p.Gly73Ser rs121912455 Missense
NM_000454.4:c.242A >G NP_000445.1:p.His81Arg rs121912458 Missense
NM_000454.4:c.256G >C NP_000445.1:p.Gly86Arg rs121912436 Missense
NM_000454.4:c.253T >G NP_000445.1:p.Leu85Val rs121912452 Missense
NM_000454.4:c.281G >C NP_000445.1:p.Gly94Ala rs121912438 Missense
NM_000454.4:c.280G >T NP_000445.1:p.Gly94Cys rs121912437 Missense
NM_000454.4:c.280G >C NP_000445.1:p.Gly94Arg rs121912437 Missense
NM_000454.4:c.289G >A NP_000445.1:p.Asp97Asn rs121912459 Missense
NM_000454.4:c.302A >G NP_000445.1:p.Glu101Gly rs121912439 Missense
NM_000454.4:c.319C >G NP_000445.1:p.Leu107Val rs121912440 Missense
LRG_652t1:c.317C >T LRG_652p1:p.Ser106Leu Missense
NM_000454.4:c.313A >T NP_000445.1:p.Ile105Phe rs121912445 Missense
NM_000454.4:c.341T >C NP_000445.1:p.Ile114Thr rs121912441 Missense
NM_000454.4:c.338T >C NP_000445.1:p.Ile113Thr rs74315452 Missense
NM_000454.4:c.358-10T >G Intron variant
NM_000454.4:c.358-11A >G Intron variant
NM_000454.4:c.380T >A NP_000445.1:p.Leu127Ter rs121912454 Stop gain
NM_000454.4:c.404G >A NP_000445.1:p.Ser135Asn rs121912451 Missense
NM_000454.4:c.436G >A NP_000445.1:p.Ala146Thr rs121912447 Missense
NM_000454.4:c.435G >C NP_000445.1:p.Leu145Phe rs1482760341 Missense
NM_000454.4:c.434T >C NP_000445.1:p.Leu145Ser rs121912446 Missense
NM_000454.4:c.455T >C NP_000445.1:p.Ile152Thr rs121912449 Missense
C9orf72
NM_001256054.2:c. − 45 +
163GGGGCC[>24] rs143561967 Intron variant
FUS
NM_004960.3:c.616G >A NP_004951.1:p.Gly206Ser rs387906628 Missense
NM_004960.3:c.646C >T NP_004951.1:p.Arg216Cys rs267606832 Missense
NM_004960.3:c.1507_1508AG [3] NP_004951.1:p.Gly504fs Frameshift
NM_004960.3:c.1483C >T NP_004951.1:p.Arg495Ter rs387906627 Stop gain
NM_004960.3:c.1520G >A NP_004951.1:p.Gly507Asp rs267606831 Missense
NM_004960.3:c.1570A >T NP_004951.1:p.Arg524Trp rs267606833 Missense
NM_004960.3:c.1562G >A NP_004951.1:p.Arg521His rs121909671 Missense
NM_004960.3:c.1561C >T NP_004951.1:p.Arg521Cys rs121909668 Missense
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Nucleotide Protein dbSNP Mutation Type
NM_004960.3:c.1561C >G NP_004951.1:p.Arg521Gly rs121909668 Missense
NM_004960.3:c.1553G >A NP_004951.1:p.Arg518Lys rs121909669 Missense
NM_004960.3:c.1551C >G NP_004951.1:p.His517Gln rs121909667 Missense
TARDBP
NM_007375.3:c.800A >G NP_031401.1:p.Asn267Ser rs80356718 Missense
NM_007375.3:c.869G >C NP_031401.1:p.Gly290Ala rs121908395 Missense
NM_007375.3:c.881G >T NP_031401.1:p.Gly294Val rs80356721 Missense
NM_007375.3:c.881G >C NP_031401.1:p.Gly294Ala rs80356721 Missense
NM_007375.3:c.883G >A NP_031401.1:p.Gly295Ser rs80356723 Missense
NM_007375.3:c.892G >A NP_031401.1:p.Gly298Ser rs4884357 Missense
NM_007375.3:c.943G >A NP_031401.1:p.Ala315Thr rs80356726 Missense
NM_007375.3:c.991C >A NP_031401.1:p.Gln331Lys rs80356727 Missense
NM_007375.3:c.1009A >G NP_031401.1:p.Met337Val rs80356730 Missense
NM_007375.3:c.1028A >G NP_031401.1:p.Gln343Arg rs80356731 Missense
NM_007375.3:c.1042G >T NP_031401.1:p.Gly348Cys rs80356733 Missense
NM_007375.3:c.1055A >G NP_031401.1:p.Asn352Ser rs80356734 Missense
NM_007375.3:c.1144G >A NP_031401.1:p.Ala382Thr rs367543041 Missense
NM_007375.3:c.1153T >G NP_031401.1:p.Trp385Gly rs797044595 Missense
A recent study, Project MinE, has begun to analyze the whole-genome sequence data of at least
15,000 patients with ALS worldwide [26]. Whole-genome sequencing is a promising tool to discover
unknown genetic variants that contribute to disease. In a pilot analysis of 1169 patients with ALS,
several rare genetic variations were found [27]. Several mutations were genetically associated with
cellular pathology, which is characterized by motor neuron degeneration due to an interplay of
axonal dysfunction, oxidative stress, mitochondrial dysfunction, microglia activation, and protein
aggregation [13,28].
3. Targeted Genome Editing Using CRISPR/Cas9
CRISPR (clustered regularly interspaced short palindromic repeats)/CRISPR-associated system
(Cas) is an immune system derived from prokaryotes that can be used to target and edit specific
sequences. CRISPR sequences are located in prokaryotes such as bacteria and archaea. New foreign
DNA fragments derived from infection are integrated into host CRISPR sequences and transcribed into
CRISPR RNA. These RNA sequences are used as a guide to recognize foreign genetic elements derived
from previously infected prokaryotes. The Cas protein is an enzyme that cleaves DNA fragments to
match the CRISPR RNA [29,30].
To use CRISPR/Cas, a researcher designs small guide RNA (sgRNA) near the proto-spacer adjacent
motif (PAM) sequences for Cas nuclease to bind target DNA sequences recognized by sgRNA. The Cas
protein-coding gene and sgRNA plasmids are usually transfected via electroporation or lipid-based
transfection agents. Other CRISPR/Cas9 delivery methods include ribonucleoprotein (RNP) complex
and packaging into lentivirus or adeno-associated virus (AAV). Once in the nucleus, Cas nuclease
binding leads to a double-strand break (DSB) in DNA that is recovered by the cell’s own repair system.
These DSBs are commonly repaired by non-homologous end joining (NHEJ) or homology-directed
repair (HDR) in the presence of a donor template. The difference between NHEJ and HDR is that
the NHEJ mechanism generates insertions and deletions (indel) at a cleavage site, resulting in the
knockout of a protein coding gene, whereas the HDR mechanism induces insertions or replaces DNA
fragments with a donor template [31,32].
Cas9 from Streptococcus pyogenes (SpCas9) is widely used for the CRISPR/Cas system. Various
other subtypes of the Cas protein, including saCas9, c2c2, RCas, and dCas, have also been identified
and developed for applications in genome editing [33]. Each Cas protein has a unique PAM sequence
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and different protein sizes for different applications. These proteins have specific cleavage targets
in DNA and RNA, and generate single-strand nicks (i.e., Cas9n) that activate or inhibit transcription
(i.e., CRISPRa or CRISPRi) [34,35].
Genome editing using CRISPR/Cas9 is used in disease research to study genetic modifications
in various cell types. Many years ago, mutagenesis or mutant transfection was widely used to
investigate the genetic effects of mutations on disease [31,36]. Since the development of reprogramming
technology, somatic cells have been used for induced pluripotent stem cell (iPSC) generation [37].
These iPSCs have the potential to differentiate into various cell types, such as neurons, liver cells,
myoblasts, and cardiomyocytes. Patient-derived iPSCs provide an unlimited source of cells with which
to study and treat disease [38–41]. For genetic disorders in particular, pathologic effects of mutations
can be investigated in iPSCs using CRISPR/Cas9 to correct mutations (Figure 2a). The correction of
specific mutations related to ALS can thus provide important insights into both verifying the pathologic
effects of these mutations and identifying targets for therapeutic interventions.
Figure 2. Strategy of clustered regularly interspaced short palindromic repeats/CRISPR-associated
system 9 (CRISPR/Cas9)-mediated gene correction. (a) Patient-derived induced pluripotent stem cells
(iPSCs) were used to perform gene correction. Isogenic cell line was generated to investigate phenotypic
changes comparing iPSCs with genetic mutation; (b) A point mutation was target specific corrected
using a donor via homology-directed repair (HDR) mechanism; (c) Repeat expansion in C9orf72 was
deleted with two sgRNAs.
In both fALS and sALS, the majority of causative genetic mutations are found in the SOD1, C9orf72,
FUS, and TARDBP genes. Most pathogenic variants are the result of missense mutations, although
repeat expansion in the intron region of the C9orf72 gene has been identified as a known cause of ALS.
Patient-derived iPSCs are an important disease model to study ALS. One drawback to patient-derived
iPSCs, however, is the phenotypic variation, which makes it difficult to determine which genetic
mutations are relevant to ALS. Here, we review recent studies that have applied CRISPR/Cas9 to
patient-derived iPSCs to study genetic mutations in ALS. These methods have included the generation
of isogenic cell lines with the same genetic background as the iPSCs to understand the genetic etiology
and pathophysiology of ALS (Table 2).
3.1. Superoxide Dismutase 1 (SOD1)
Mutant SOD1 was the first gene to be linked to ALS. SOD1 is located on chromosome 21q22.1 and
contains five exons. More than 100 SOD1 mutations have been identified, 30 of which are associated
with ALS, according to the genomAD and ClinVar online databases [42]. Mutations in SOD1 are
reported in ~12% of fALS and ~1% of sALS cases [25,43]. SOD1 is an antioxidant enzyme that binds to
copper and zinc to break down superoxide radicals, preventing cell damage. Mutations in SOD1 lead
to neuronal excitability, endoplasmic reticulum stress, mitochondrial dysfunction, oxidative stress,
impaired protein transport, accumulation of misfolded SOD1 protein, and inflammation, all of which
may increase cell death [44,45].
A recent study [46] conducted a targeted gene correction of the SOD1 A272C mutation
in patient-derived iPSCs. Fibroblasts harboring the A272C mutation were obtained from a patient
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with ALS and reprogrammed to generate iPSCs. Guide RNA was designed to include a PAM
sequence that targeted the A272C mutation. A donor template to replace this point mutation was
co-transfected with Cas9 nuclease and sgRNA via electroporation (Figure 2b). Because ALS is an MND,
patient-derived iPSCs and the gene-corrected isogenic cell line were differentiated into motor neurons
to compare neuronal differentiation capacity. RNA sequencing revealed significantly altered gene
expression between the patient-derived motor neurons and the gene-corrected isogenic motor neurons.
Gene ontology analysis revealed that expression was altered in RNA related to nervous system
activity, signal transduction, and endoplasmic reticulum homeostasis. A similar study [47] applied
this CRISPR/Cas9 gene-correction strategy to the SOD1 E100G mutation. Targeted gene correction was
performed in iPSCs derived from a patient with the E100G mutation, which then were differentiated
into motor neurons. Correction of the SOD1 E100G mutation in an isogenic cell line increased
motor neuron proportion, soma size, and neurite length and decreased cell death. Transcriptional
changes detected by RNA sequencing identified several up- or down-regulated pathways, including
those related to AP1, oxidative phosphorylation, and ion channel transport. The functional gene
network showed that these pathways share functional interactions and cascades. On the basis of these
results, the authors hypothesized that activated ERK and JNK signaling is critical to neurodegeneration
in mutant SOD1 motor neurons. Treatment with small-molecule inhibitors that target ERK, MAPK, JNK,
WNT, TP53, and CDK kinases decreased motor neuron degeneration, suggesting that these pathways
are critical in SOD1-linked ALS. A study by Imamura et al. [48] used CRISPR/Cas9-mediated gene
corrected cell lines in drug screening assay as a control. iPSCs were generated from one ALS patient
carrying the L144FVX mutation in the SOD1 gene and mutation was corrected by inserting wild type
SOD1 sequences with homologous arms. The corrected cell line showed reversal of SOD1-associated
pathologic phenotype, including increased motor neurons survival, degradation of misfolded SOD1
protein, and reserved internal ATP level. On the other hand, high-throughput screening discovered
that more than half of hit targeted the Src/c-Abl signaling pathway in motor neurons differentiated
from iPSCs. The treatment of bosutinib, one of the directly inhibited Src/c-Abl, showed therapeutic
effects on motor neurons’ survival, decreased phosphorylation of Src/c-Abl, promoted autophagy
activity, adecreased misfolded mutant SOD1, and rescue of ATP, as did gene correction of L144FVX.
In this study, the authors revealed the potential application of the gene corrected isogenic cell line used
as a control to validate the therapeutic effects of drugs on ALS disease.
3.2. C9orf72
The hexanucleotide (G4C2) repeat expansion in C9orf72 is the most common genetic cause of ALS
and is also common in frontotemporal dementia (FTD). This repeat expansion is responsible for up to 40%
of fALS and 7% of sALS cases [25,43,49]. The repeat is located in intron1 of the C9orf72 gene. The number
of repeats is highly variable within an individual, ranging from hundreds to thousands of repeats;
less than 30 repeats is considered normal [50]. Mutant C9orf72 has several pathologic neurodegenerative
phenotypes, including reduced protein expression levels, promoter hypermethylation, excitotoxicity,
RNA foci formation, and generation of dipeptide repeats (DPRs). Transcription of this repeat
expansion produces RNA with abnormal secondary structures that aggregate to form intranuclear foci,
which results in the disruption of transcription and cytoplasmic transport [51,52]. Repeat-associated
non-AUG (RAN) translation produces toxic DPR proteins [53]. Poly GR(glycine arginine), one of the
dipeptide chains, is accumulated in patients with C9orf72-associated ALS and FTD [54,55].
Mutant C9orf72 genes with 800–1050 repeats from patients with ALS are also associated with
RNA foci formation and hypermethylation [56]. CRISPR/Cas9 genome editing technology with two
sgRNAs has been designed to excise repeat expansions via the cleavage and removal of the repeat
region (Figure 2c). Deletion of the repeat expansion results in decreased RNA foci formation and
reduces methylation in repeat knockout iPSC-derived neurons. In contrast, deletion of the normal
allele did not reverse the methylation level, which indicates that the hexanucleotide (G4C2) expansion
is the cause of hypermethylation within the GC-rich region of C9orf72. Another study that used iPSC
Int. J. Mol. Sci. 2020, 21, 3801 7 of 15
lines with up to 638, 760, and 960 repeats in C9orf72 showed that the C9orf72 mutation increased AMPA
receptor expression, leading to enhanced excitotoxicity via intracellular Ca2+ overload [57], as well as
RNA foci formation and DPR toxicity, but no differences in neuron excitability in iPSC-derived motor
neurons were observed. A genome-editing approach that deleted the repeat expansion was able to
rescue the AMPA-induced excitotoxicity and reduced the RNA foci formation and DPR expression.
RNA sequencing also showed that deletion of the repeat expansion altered the gene expression
in genes related to RNA processing, protein targeting, nuclear transport, synaptic transmission, and
the regulation of phosphate metabolism [58].
Unlike the hSOD1 G93A transgenic mouse model, deletion of C9orf72 in the mouse does not
produce an ALS-like phenotype [59]. As an alternative, Drosophila expressing 58 repeats of G4C2 or
poly GR overexpression has been used to investigate the involvement of the Ku80 protein in ALS
neurodegeneration [60,61]. Studies have confirmed that Ku80 protein levels are increased in both
this Drosophila model and in C9orf72 iPSC-derived motor neurons with 70, 590, 1000, or 1100 repeats
in each cell line. Ku80 is an essential DNA repair protein. The elevated expression of Ku80 leads
to an increase in downstream pro-apoptotic proteins such as PUMA, BAX, and cleaved caspase-3.
The application of genome editing using two sgRNAs reduced Ku80 levels and prevented nuclear RNA
foci formation in iPSC-derived motor neurons with the corrected repeat expansion. Using CRISPR/Cas9,
one copy of Ku80 in the C9orf72 iPSC was deleted, which resulted in the reduction of Ku80 expression
as well as PUMA and cleaved caspase-3 levels. These studies, therefore, demonstrate that the
CRISPR/Cas9 approach can be applied to the C9orf72 repeat expansion to validate pathologic phenotypes
in patient-derived iPSCs and identify gene-based therapeutic approaches.
3.3. Fused in Sarcoma (FUS)
The fused in sarcoma (FUS) gene encodes an RNA-binding protein that is located primarily
in the nucleus and composed of seven domains: QGSY-rich, Gly-rich, RNA recognition motif
(RRM), Arg-Gly-Gly1 (RGG1), zinc finger (ZnF), RGG2, and nuclear localization signal (NLS) [62].
The majority of disease-causing FUS mutations are heterozygous with an autosomal-dominant
inheritance pattern [63]. In addition, most FUS mutations affect the C-terminal nuclear localization
signal. The known functions of FUS include DNA damage repair, transcription, and splicing [64].
The effect of mutant FUS in neurodegeneration and other biological processes is unknown; however,
one hallmark of mutant FUS is cytoplasmic mislocalization, which may be related to a toxic gain of
function in the cytoplasm [65]. Previous findings have suggested that mutant FUS may impact DNA
repair, energy metabolism, and axonal transport. Recent studies have used CRISPR/Cas9 gene editing
to study the impact of mutant FUS on ALS pathologic phenotypes in patient-derived iPSCs. A study by
Wang et al. [46] first demonstrated CRISPR/Cas9-mediated gene correction of the FUS G1566A missense
mutation in ALS patient-derived iPSCs. Another study used the CRISPR/Cas9 system to correct the
recessive FUS H517Q mutation to the wild-type sequence in patient-derived iPSCs. Both mutant and
corrected iPSCs were differentiated into Isl1/Tuj1-positive motor neurons to investigate the expression
of the MAPK family. These results showed that both p38 and ERK kinase are activated in mutant FUS,
indicating that the activation of MAPK signaling is a key pathway in FUS-mediated neurodegeneration
in ALS [47]. Motor neurons derived from patients with ALS with the FUS mutation typically show
cytoplasmic mislocalization [64]. Motor neurons carrying the FUS P525L and R521H mutations also
exhibit mislocalization of FUS, compared with no aggregation in healthy control cells.
Electrophysiological changes and defects in axonal transport have also been observed in motor
neurons with mutant FUS. The movement of endoplasmic reticulum vesicles is also significantly
reduced, which results in impaired axonal transport [66]. To confirm whether these observed pathologic
phenotypes were the result of the FUS mutation, CRISPR/Cas9-mediated gene correction was applied
to iPSCs derived from patients with the FUS R521H mutation. Isogenic cell lines with the same genetic
background as the mutant iPSCs were also established. Mitochondrial transport experiments showed
that gene correction rescued the number of total and moving mitochondria as well as cytoplasmic
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FUS localization. Moreover, these experiments found that an HDAC6 inhibitor is an effective drug for
targeting axonal transport impairment. This study thus demonstrates that gene correction can mediate
the investigation of FUS-related disease pathologic phenotypes and may have the potential to be used
for therapeutic discovery and validation.
Oxidative stress promotes genome damage and neurodegeneration results in motor neuron death,
which is consistent with increased markers of oxidative stress in patients with ALS [67,68]. In healthy
neurons, FUS is localized predominantly to the nucleus and promotes genome repair by recruiting
PARP-1 dependent XRCC1/DNA ligase IIIα (LigIII) in response to DNA damage response (DDR)
signaling [69]. ALS patient-derived motor neurons with FUS P525L and R521H mutations exhibit
an approximately threefold increase in the cytoplasmic accumulation of FUS as well as a cytotoxic
response to H2O2 and >50% decreased efficiency of nick ligation owing to the delay of DNA break
repair [70]. Gene-corrected isogenic cell lines have been established using CRISPR/Cas9 to investigate
the direct attribution of FUS mutations to DNA ligation impairment. Correction of these FUS mutations
rescued DNA ligation defects, as assessed by ligation assay, and DNA integrity was also restored,
indicating that mutant FUS fails to correct DNA ligation defects caused by oxidative stress. This study
suggests that LigIII function may be a therapeutic target in patients with FUS mutations.
Energy metabolism is a critical component in neurodegeneration as well as genome repair, because
most biological processes, including neuronal firing and axonal transport, are energy demanding [71,72].
The elevation of glycogen stores observed in patients with ALS implies a defect in mitochondrial
function and a failure in glucose matabolism, which has been hypothesized to cause the hallmark motor
neuron degeneration in ALS. Mislocalization caused by mutant FUS increased enzymatic interactions
in glucose metabolism [73], indicating that energy metabolism may be involved in FUS-related ALS
degeneration. Substrate-tracing experiments using radiolabeled 13C6—glucose and 13C3—lactate
reveal the involvement of oxidative metabolism, but not the glycolytic pathway in motor neurons
differentiated from iPSCs. In motor neurons carrying an FUS mutation, however, there was no evidence
of altered mitochondrial morphology, such as intermembrane space and cristae patterns, as measured
by transmission electron microscopy (TEM), whereas FUS overexpression was associated with a defect
in the mitochondrial structure. Radioactive tracer analysis using 13C was performed to investigate
FUS-related changes in glucose and/or lactate metabolism in FUS-mutant versus gene-corrected motor
neurons. Although lactate was revealed as a main energy source in motor neurons, there was no altered
contribution of glucose or lactate to glycolytic or TCA metabolites after gene correction, indicating that
there is no metabolic dysfunction in FUS-related ALS phenotypes [5]. The use of CRISPR/Cas9 genome
editing in patient-derived iPSCs also reveals that mutant FUS does not alter metabolic pathways,
providing further evidence that metabolic dysfunction is not involved in FUS-related ALS.
3.4. TAR-Binding Protein Gene (TARDBP)
The TARDBP gene is located on chromosome 1p36.22 and contains six exons encoding TAR-DNA
binding protein TDP-43. It is a DNA/RNA binding protein and functions in a variety of RNA
metabolism such as splicing, stability, and trafficking. Mutations in TARDBP gene were first
reported by Sreedharan et al. in 2008 [74]. Since then, many mutations have been identified
through genetic analysis in ALS patients, and most mutations are conserved within exon 6 of
the TARDBP gene, which encodes the carboxy-terminal glycine-rich domain [75]. TDP-43 protein
undergoes post-translational modification including ubiquitination, phosphorylation, acetylation,
cysteine oxidation, and PARylation. Ubiquitinated and hyper-phosphorylated TDP-43 forms
cytoplasmic inclusion bodies—a pathological hallmark of ALS. Mutations in the C-terminal region
hasten aggregations, mislocalization to the cytoplasm, and cytotoxicity [76].
In the nervous system, brain-derived neurotrophic factor (BDNF) is essential for neuron survival,
differentiation, and synaptic plasticity. It is produced and regulated to the secretory pathway in neurons
by binding of Sortilin (encoded by sort1 gene) to the pro-domain of BDNF. TDP-43 regulates the splicing
of mRNA encoding Sortilin. Loss of TDP-43 leads to the generation of isoform owing to additional
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exon 17b and soluble Sortilin protein. Therefore, a study by Tann et al. hypothesized that TDP-43
dysfunction caused by mutations in TARDBP gene altered BDNF secretion and synaptic plasticity [77].
In a mouse model, the authors confirmed that hippocampal CA1-specific knockout of TDP-43 increased
exon 17b mRNA of sort1 mRNA and reduced dendrite complexity and spine. To investigate the effect
mutations could have in human neurons, CRISPR/Cas9 was used to correct M337V in three iPSCs
lines from a patient. Corrected iPSCs were differentiated into excitatory cortico/hippocampal-like
neurons. All isogenic lines showed a similar mRNA level of TARDBP and SORT1, but a decreased
level of exon 17b mRNA of sort1 compared with cells bearing M337V. Lentivirus expressing human
pro-BDNF was transduced to neurons and to assess BDNF secretion. M337V displayed a decreased
level of BDNF, and significantly increased in all isogenic gene corrected neurons. This study indicated
that TDP-43 mutation is associated to Sortilin isoform and BDNF secretion, and the gene correction
strategy demonstrated that M337V mutation in TARDBP is a direct cause of abnormal BDNF secretion.
4. CRISPR/Cas9-Mediated In Vivo Therapeutic Approach
A transgenic mouse model that overexpresses the human SOD1 G93A mutation is widely used
in studies of ALS. This mouse model expresses a similar pathologic phenotype to human ALS, including
short survival and loss of motor behavior function. Recent studies using this mouse model [78,79]
have reported that CRISPR/Cas9 disturbs the expression of mutant SOD1, which may be a promising
potential therapeutic strategy. These studies have hypothesized that the reduced expression of mutant
protein reverses the disease phenotype.
Table 2. Studies of clustered regularly interspaced short palindromic repeats/CRISPR-associated system
9 (CRISPR/Cas9)-mediated genome editing in amyotrophic lateral sclerosis. N/R, not recorded; ALS,
amyotrophic lateral sclerosis; iPSC, induced pluripotent stem cell; FTD, frontotemporal dementia.
Study Gene Variants Model Gene EditingEfficiency
Homologous recombination
Wang et al., 2017 [46] SOD1 A272C Human ALS patient-derived iPSCs 20%
Bhinge et al., 2017 [47] SOD1 E100G Human ALS patient-derived iPSCs 0.5% (one of ~ 180colonies)
Imamura et al., 2017 [48] SOD1 L144FVX Human ALS patient-derived iPSCs Selected withpuromycin
Guo et al., 2017 [66] FUS R521H Human ALS patient-derived iPSCs Selected withpuromycin
Wang et al., 2017 [46] FUS G1566A Human ALS patient-derived iPSCs 1%
Bhinge et al., 2017 [47] FUS H517Q Human ALS patient-derived iPSCs 0.5% (one of ~ 180colonies)
Wang et al., 2018 [70] FUS R521H, P525L Human ALS patient-derived iPSCs Selected withpuromycin
Vandoorne et al., 2019 [5] FUS R521H, P525L Human ALS patient-derived iPSCs Selected withpuromycin
Tann et al., 2019 [77] TARDBP M337V Human ALS patient-derived iPSCs FACS sorting
Deletion
Pribadi et al., 2016 [56] C9orf72 GGGGCC Human FTD/ALS patient-derivediPSCs
11.1% (66 of 593
colonies)
Selvaraj et al., 2018 [58] C9orf72 GGGGCC Human ALS patient-derived iPSCs 0.6% ~ 4.5%
Lopez-Gonzalez et al., 2019 [61] C9orf72 GGGGCC C9orf72 patient-derived iPSCs N/R
Duan et al., 2019 [79] SOD1 G93A hSOD1 G93A transgenic mouse N/R
Indel formation
Gaj et al., 2017 [78] SOD1 G93A hSOD1 G93A transgenic mouse N/R
Several sgRNAs that do not overlap with the G93A mutation have been designed for application
to other SOD1 mutations. For in vivo genome editing such as that using animal models, AAV is the
safest delivery vehicle. Because AAV has a limited capacity to harbor the plasmid, however, Cas9
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nuclease from Staphylococcus aureus (SaCas9) is often used, thanks to its smaller size than spCas9 [80].
The plasmid, consisting of SaCas9 under the CMV promoter and sgRNA under the U6 promoter,
is packaged into AAV. In a study of the hSOD1 G93A mouse model, this AAV was injected via the facial
vein at postnatal day 0–1. Four weeks after injection, Western blot and histological analysis confirmed
reduced expression of the SOD1 protein and an increased number of motor neurons in the lumbar
spinal cord. Furthermore, these findings showed that genome editing improved motor function,
reduced muscle atrophy, delayed disease onset, and increased survival compared with a control model.
Taken together, studies using CRISPR/Cas9-mediated in vivo genome editing of missense
mutations in SOD1 show that this technique can be used not only to identify the underlying molecular
mechanism but also to reverse the pathologic phenotype in patient-derived disease models, and thus
may play a potential role in gene therapy for ALS.
5. Conclusions and Future
In this review, we discussed recent studies that have used CRISPR/Cas9-mediated gene correction
to investigate the pathophysiology of ALS using patient-derived iPSCs. Although CRISPR/Cas9
technology is simple and easy to use across several research applications, there remain limitations with
this approach. One critical concern is off-target effects, which could occur if the specificities of Cas9 and
sgRNA are reduced such that they recognize and cleave non-target DNA sites [81]. Another limitation
is the low (<1%) efficiency of gene correction through the HDR mechanism. Techniques such as timed
delivery with cell cycle synchronization [82,83] and suppression of NHEJ key molecules [84] are needed
to enhance HDR genome engineering rates.
As mutant SOD1 was revealed as a genetic cause of ALS in 1993, over 20 genes associated with
ALS have been identified; however, more than 80% of patients with ALS do not exhibit known genetic
variants [85]. Clinical differences between patients may imply that multiple mechanisms are involved
with various genetic causes. According to ALSoD, over 100 genes are listed as ALS-associated genes.
Recently, Vildan et al. analyzed SOD1, C9orf72, FUS, TARDBP, and UBQLN2 to find common genetic
alterations in 30 patients with ALS [86]. In addition, many European countries and the United States
have joined Project MinE to analyze the genes of 15,000 patients with ALS and 7500 controls. The aim
of this project is to better understand the genetic background of ALS. Online open access resources
also exist to obtain information about gene variants in various diseases, including ClinVar and Miner.
The application of genetic information, advanced methods in genome engineering with CRISPR/Cas9,
and in vitro disease modeling using iPSCs is likely to facilitate the discovery of disease-causing
mutations and further investigate the underlying pathophysiology of various diseases. It is the hope
that this strategy will ultimately lead to a thorough investigation of the various mechanisms underlying
ALS to identify treatments and a cure for ALS.
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